tough quarter hard trokendi xr oxtellar xr dynam improv much
supernu report dilut ep revenu compar street
estim respect though inventori headwind pressur sale
manag also cite neg impact higher gross-to-net spread due
season factor annual deduct reset greater subsid patient out-of-
pocket cost suggest payer headwind would short-liv regard
trokendi xr sure light evolv competit dynam
migrain prophylaxi class given avail anti-cgrp agent
competit coupl trend toward tighter payer control footprint trokendi
xr grown beyond prescript rx growth trajectori trokendi xr
oxtellar xr still sluggish reiter neutral rate lower pt
frm owe mainli lower trokendi xr oxtellar xr estim
season new realiti sale trokendi xr
versu sale though inventori headwind net stock
season factor lost us continu concern regard
volum trajectori trokendi xr rx trokendi xr declin
sequenti versu show modest quarter-to-d
qtd growth rate versu per iqvia regard net sales/net
price certainli exampl manag team set
temper expect certain product owe payer challeng allergan
yesterday cite steeper product heavili contract class name
linzess glaucoma product put anoth way combin payer
exert control brand footprint grow context abil
step patient gener challeng competit
migrain prophylaxi space teva lilli contract aggress
given backdrop wonder realist manag reiter
net sale guidanc rang
oxtellar xr yet show sign acceler sale oxtellar xr
sale yet see notic inflect
volum growth trajectori oxtellar xr rx declin sequenti
grow qtd follow monotherapi label
expans decemb continu take cautiou approach epilepsi
monotherapi opportun bear mind oxcarbazepin gener speak
well-known quantiti broader neurolog commun given alreadi
fair amount usag oxtellar xr monotherapi accord
oxtellar xr rx written monotherapi
case label expans enabl call significantli differ physician
audienc case trokendi xr label expans migrain prophylaxi
commerci risk epilepsi product clinic risk adhd pipelin
supernu focus treatment disord
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
consensu estim
compani report factset pjc estim
compani report pjc estim
page
million except per shareactualpjc estimatesrevenuetrokendi xr er xr er consensu consensu outstand except per guidanceestimatestot product
consensu
compani report factset pjc estim
page
million except per sharecurrentpriorcurrentpriorcurrentpriorcurrentpriorcurrentpriorrevenuestrokendi xr er xr er gener oper incom expens tax provis outstand supernu quarterli annual incom statement
million except ep
sale
sell gener administr
incom loss tax
expens total revenu
sell gener administr
royalti sale partner product includ payment unit relat fda approv orenitram receipt payment relat royalti stream orenitram
proprietari piper jaffray co may
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
million
net chang asset liabil
acquisit tangibl asset
acquisit intang
stock option issuanc
proprietari piper jaffray co may
page
million
proprietari piper jaffray co may
page
